Thyrocare Technologies Ltd (IN:THYROCARE)
:THYROCARE
Want to see IN:THYROCARE full AI Analyst Report?
THYROCARE Stock Chart & Stats
₹459.10
-₹16.20(-1.70%)
At close: 4:00 PM EST
₹459.10
-₹16.20(-1.70%)
Day’s Range― - ―
52-Week Range₹230.78 - ₹537.97
Previous CloseN/A
Volume114.81K
Average Volume (3M)56.30K
Market Cap
₹63.44B
Enterprise Value₹20.37B
Total Cash (Recent Filing)₹1.92B
Total Debt (Recent Filing)₹246.80M
Price to Earnings (P/E)61.2
Beta0.57
Next Earnings
May 21, 2026EPS Estimate
8.2Next Dividend Ex-DateN/A
Dividend Yield0.68%
Share Statistics
EPS (TTM)4.30
Shares Outstanding159,165,310
10 Day Avg. Volume44,587
30 Day Avg. Volume56,302
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.35
Price to Sales (P/S)1.87
P/FCF Ratio8.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.1
Revenue Forecast (FY)₹9.48B
Bulls Say, Bears Say
Bulls Say
Centralized Automated Lab ModelThyrocare’s centralized, automated laboratory footprint with a broad test menu and extensive collection partner network creates durable scale advantages. Centralized processing lowers per-test costs, improves quality control, and raises barriers to entry versus fragmented local labs, supporting margin sustainability and capacity expansion over the medium term.
Sustained Top-line And EPS GrowthConsistent double-digit revenue growth and very strong EPS growth indicate robust demand and operating leverage in core diagnostic services. This trend supports reinvestment in lab capacity and distribution, funds margin improvement initiatives, and provides a durable earnings base even as the company scales its collection network and test volumes.
Healthy Balance Sheet And Cash GenerationA strong equity base, low leverage and rising operating cash flow give Thyrocare financial flexibility to fund expansion, absorb cyclical shocks, and pursue targeted investments. Positive free cash flow growth implies high-quality earnings and the ability to self-fund capacity upgrades without materially increasing refinancing risk.
Bears Say
Significant Capital Expenditure NeedsSustained or sizable capex requirements for lab automation and network expansion can materially draw on free cash flow despite positive operating cash flow. Over 2–6 months, elevated capex can limit discretionary spending, slow deleveraging, and constrain the pace of new initiatives if revenue ramps slower than expected.
Slight Net Margin CompressionA decline in net margins, even if modest, signals cost or financing pressure at the bottom line. If margin compression persists it reduces cash conversion and leaves less room for reinvestment or pricing flexibility, increasing vulnerability to competitive pricing and higher input or labor costs over the medium term.
Small Increase In Total DebtEven a modest rise in debt raises interest and refinancing exposure, particularly when paired with ongoing capex. That uptick can erode financial flexibility and marginally increase funding costs, making the balance sheet more sensitive to slower cash flow or adverse rate moves over the coming months.
Thyrocare Technologies Ltd News
THYROCARE FAQ
What was Thyrocare Technologies Ltd’s price range in the past 12 months?
Thyrocare Technologies Ltd lowest stock price was ₹230.78 and its highest was ₹537.97 in the past 12 months.
What is Thyrocare Technologies Ltd’s market cap?
Thyrocare Technologies Ltd’s market cap is ₹63.44B.
When is Thyrocare Technologies Ltd’s upcoming earnings report date?
Thyrocare Technologies Ltd’s upcoming earnings report date is May 21, 2026 which is in 30 days.
How were Thyrocare Technologies Ltd’s earnings last quarter?
Thyrocare Technologies Ltd released its earnings results on Jan 28, 2026. The company reported ₹4.3 earnings per share for the quarter, missing the consensus estimate of ₹4.5 by -₹0.2.
Is Thyrocare Technologies Ltd overvalued?
According to Wall Street analysts Thyrocare Technologies Ltd’s price is currently Overvalued.
Does Thyrocare Technologies Ltd pay dividends?
Thyrocare Technologies Ltd pays a Quarterly dividend of ₹2.333 which represents an annual dividend yield of 0.68%. See more information on Thyrocare Technologies Ltd dividends here
What is Thyrocare Technologies Ltd’s EPS estimate?
Thyrocare Technologies Ltd’s EPS estimate is 8.2.
How many shares outstanding does Thyrocare Technologies Ltd have?
Thyrocare Technologies Ltd has 159,165,310 shares outstanding.
What happened to Thyrocare Technologies Ltd’s price movement after its last earnings report?
Thyrocare Technologies Ltd reported an EPS of ₹4.3 in its last earnings report, missing expectations of ₹4.5. Following the earnings report the stock price went up 1.313%.
Which hedge fund is a major shareholder of Thyrocare Technologies Ltd?
Currently, no hedge funds are holding shares in IN:THYROCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Thyrocare Technologies Ltd
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include 34 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
Technical Analysis
Krsnaa Diagnostics Limited
―
Medi Assist Healthcare Services Limited
―
Metropolis Healthcare Ltd.
―
Morepen Laboratories Limited
―
Vijaya Diagnostic Centre Ltd.
―